{"name":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","slug":"shanghai-chia-tai-tianqing-pharmaceutical-technology-development-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"TQH2722 injection","genericName":"TQH2722 injection","slug":"tqh2722-injection","indication":"Other","status":"phase_3"},{"name":"Placebo of TQC2731","genericName":"Placebo of TQC2731","slug":"placebo-of-tqc2731","indication":"Other","status":"phase_3"},{"name":"TQB2934 injection","genericName":"TQB2934 injection","slug":"tqb2934-injection","indication":"Other","status":"phase_1"},{"name":"Placebo of TQH2722 injection","genericName":"Placebo of TQH2722 injection","slug":"placebo-of-tqh2722-injection","indication":"Other","status":"phase_3"},{"name":"TQC2731 injection","genericName":"TQC2731 injection","slug":"tqc2731-injection","indication":"Other","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TQB2825 Injection","genericName":"TQB2825 Injection","slug":"tqb2825-injection","indication":"Non-small cell lung cancer","status":"phase_3"}]}],"pipeline":[{"name":"TQH2722 injection","genericName":"TQH2722 injection","slug":"tqh2722-injection","phase":"phase_3","mechanism":"TQH2722 injection's mechanism is not publicly available.","indications":[],"catalyst":""},{"name":"Placebo of TQC2731","genericName":"Placebo of TQC2731","slug":"placebo-of-tqc2731","phase":"phase_3","mechanism":"This is a placebo control arm and contains no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"TQB2825 Injection","genericName":"TQB2825 Injection","slug":"tqb2825-injection","phase":"phase_3","mechanism":"TQB2825 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"TQB2934 injection","genericName":"TQB2934 injection","slug":"tqb2934-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo of TQH2722 injection","genericName":"Placebo of TQH2722 injection","slug":"placebo-of-tqh2722-injection","phase":"phase_3","mechanism":"This is a placebo control with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"TQC2731 injection","genericName":"TQC2731 injection","slug":"tqc2731-injection","phase":"phase_3","mechanism":"TQC2731 injection's mechanism is not publicly available.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPd2p4RHowNHR3Y3VRTVJRLXE4VnhTN2hZZFBBUGV4RjFsUXp0UlZXQ3d4V2hyM2xFM1FEeWx2Z1FaTWVBV2k5SjVneGVGbVg3cFowMzlwRklPMDZSS01pTWJiQUE5TkRqcUN5emdzSjdXUnFwZlB1ZG80cllvdGpUMTBYenRWN0EtV1VWUUlnbDV6VVdBTlNWcg?oc=5","date":"2026-02-16","type":"pipeline","source":"Financial Times","summary":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight – Company Announcement - FT.com - Financial Times","headline":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOd1p5eUVSN2hiWWtQVTRtdUpxaWExSXZ6OHJfd3U4eFVrWFdxeGtLMlNUa2diSFZBeFZ2bTJQb1U4Z3pVNDQzRldaMUhtSVQ1bHZMY0FabXZaOUhBNFV3bDI1NEdnWC0zaXhuWmRmRXFVMzJIc29hMmlFeU5Pd0QxYzRUWTkzbVE?oc=5","date":"2025-09-19","type":"pipeline","source":"BioWorld News","summary":"Genfleet raises $234M with Hong Kong IPO - BioWorld News","headline":"Genfleet raises $234M with Hong Kong IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQd3FBTE9tSFhFOG1MMTJyZDNuSFc4aHdYY1paY0RYN0pGdXdKZF9KMG9XdWJoS3d6QnFjTVF3QUhBTjZYcEV6TEdrUUREcjF0Sjk0TTIwbzF3UDN3bk9BNmpPSGh1bEhRMmJRTUxJM0s0T3lKeEFTcVFGSVVqbTVoT1EzbzhpdVhzOUtldW8wTmtUdw?oc=5","date":"2025-05-20","type":"trial","source":"Yahoo Finance","summary":"Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - Yahoo Finance","headline":"Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOVzE5VHptbEVTRk9FOGpEWGh3M0hEM3BVbDhHd3NkOEMtU3RtNW9PcE1nbHZiQ1dSUno5cTRabXlkcUxNYUR4dDNvcGJVMi1vNlhaTE9WZ3NtcnVmOXp4SFdsVTN5aWZvQXlseVZ0blZJSlFCdXlMQzMtMnFLc2ltd09oWDMxb0gtZFBNRU9ER1pPYXlnZTFSUXNRWTVMV3EtbUlj?oc=5","date":"2025-03-11","type":"deal","source":"BioWorld News","summary":"MASH field still hot as Boehringer axes $870M deal with Yuhan - BioWorld News","headline":"MASH field still hot as Boehringer axes $870M deal with Yuhan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQbGl2VE0yR1dLRXdpTnJIcC12REhSbnhaRDBsc25uNFBnNkYteF82MXU4emdNLTFFVzlIQWExVG1ocXkzZlRsbFlibE81Y1JoejU5ei1EMFJDYjlLSEwydlEtRmFBTk1YRnhGdl9Wc2FzT3hkcHVNTFJTaWQ5ZU9zS0dhUFNJOU9hX0I1TVB5VEZib3ZhaDg3RS1EcnhjSXpnZmgyeA?oc=5","date":"2024-11-13","type":"deal","source":"BioWorld News","summary":"Apollo signs near-$1B deal for Sunshine’s FGF21/GLP-1 injection - BioWorld News","headline":"Apollo signs near-$1B deal for Sunshine’s FGF21/GLP-1 injection","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":5,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}